← FDA DRUG APPROVALS

FDA ANDA · ANDA208518

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

doxylamine succinate and pyridoxine hydrochloride, delayed release tablets 10 mg/10 mg

Sponsor: PH HEALTH

APPLICATION
ANDA208518
TYPE
ANDA
ORIGINAL APPROVAL
2017-12-06
LATEST ACTION
2020-02-24
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDEPrescription
DOXYLAMINE SUCCINATE 10MG, PYRIDOXINE HYDROCHLORIDE 10MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2020-02-24Labeling · Supplement 1 · standardAP
2017-12-06UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →